Avarofloxacin (JNJ-Q2) 是一种广谱氟喹诺酮类抗菌药物，用于治疗急性细菌性皮肤感染以及获得性肺炎。Avarofloxacin (JNJ-Q2) 盐酸阿氟沙星是一种氨基乙基哌啶氟喹诺酮，对许多革兰氏阳性菌具有抗菌作用，平均 MIC90 值为 0.12 mg/L。Avarofloxacin (JNJ-Q2) 具有治疗耐甲氧西林金黄色葡萄球菌（MRSA）感染的潜力。
CAS：878592-87-1
分子式：C21H23F2N3O4
分子量：419.42
纯度：98%
存储：Store at -20°C

Background:

Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia[1]. Avarofloxacin (JNJ-Q2) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value[2]. Avarofloxacin (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections[3].

[1]. Jones TM, et al. Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. [2]. Kocsis B, et al. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016 May 23;15(1):34. [3]. Farrell DJ, et al. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother. 2011 Jul;55(7):3631-4.